György  Bodoky
György Bodoky
oncologist at St.László kórház
Verified email at hungarnet.hu
Title
Cited by
Cited by
Year
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
E Van Cutsem, CH Köhne, E Hitre, J Zaluski, CR Chang Chien, ...
New England Journal of Medicine 360 (14), 1408-1417, 2009
39592009
Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer
JY Douillard, KS Oliner, S Siena, J Tabernero, R Burkes, M Barugel, ...
New England Journal of Medicine 369 (11), 1023-1034, 2013
18672013
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with …
JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ...
Journal of clinical oncology 28 (31), 4697-4705, 2010
17582010
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a …
H Wilke, K Muro, E Van Cutsem, SC Oh, G Bodoky, Y Shimada, ...
The lancet oncology 15 (11), 1224-1235, 2014
14512014
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
J Bruix, S Qin, P Merle, A Granito, YH Huang, G Bodoky, M Pracht, ...
The Lancet 389 (10064), 56-66, 2017
14412017
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E Van Cutsem, A Cervantes, R Adam, A Sobrero, JH Van Krieken, ...
Annals of Oncology 27 (8), 1386-1422, 2016
14242016
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making
HJ Schmoll, E Van Cutsem, A Stein, V Valentini, B Glimelius, ...
Annals of oncology 23 (10), 2479-2516, 2012
12742012
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 …
AD Roth, S Tejpar, M Delorenzi, P Yan, R Fiocca, D Klingbiel, D Dietrich, ...
Journal of clinical oncology 28 (3), 466-474, 2010
10662010
ESPEN guidelines on enteral nutrition: non-surgical oncology
J Arends, G Bodoky, F Bozzetti, K Fearon, M Muscaritoli, G Selga, ...
Clinical nutrition 25 (2), 245-259, 2006
8062006
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ...
The lancet oncology 14 (6), 490-499, 2013
7162013
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer …
R Herrmann, G Bodoky, T Ruhstaller, B Glimelius, E Bajetta, J Schuller, ...
Journal of Clinical Oncology 25 (16), 2212-2217, 2007
6512007
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
JA Ajani, W Rodriguez, G Bodoky, V Moiseyenko, M Lichinitser, ...
Journal of clinical oncology 28 (9), 1547-1553, 2010
6012010
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open …
A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ...
The Lancet 387 (10018), 545-557, 2016
5682016
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with …
J Tabernero, T Yoshino, AL Cohn, R Obermannova, G Bodoky, ...
The Lancet Oncology 16 (5), 499-508, 2015
5662015
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3
E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ...
Journal of Clinical Oncology 27 (19), 3117-3125, 2009
5002009
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
4782012
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer
JY Douillard, S Siena, J Cassidy, J Tabernero, R Burkes, M Barugel, ...
Annals of Oncology 25 (7), 1346-1355, 2014
3742014
A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with …
JR Hecht, T Trarbach, E Jaeger, J Hainsworth, R Wolff, K Lloyd, G Bodoky, ...
Journal of Clinical Oncology 23 (16_suppl), LBA3-LBA3, 2005
2542005
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
V Hess, B Glimelius, P Grawe, D Dietrich, G Bodoky, T Ruhstaller, ...
The lancet oncology 9 (2), 132-138, 2008
2192008
Randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts).(PETACC 3)
E Van Cutsem, R Labianca, D Hossfeld, G Bodoky, A Roth, E Aranda, ...
Journal of Clinical Oncology 23 (16_suppl), LBA8-LBA8, 2005
1952005
The system can't perform the operation now. Try again later.
Articles 1–20